Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
Authors' conclusion
Tofacitinib provided clinical benefit across patients with rheumatoid arthritis with a range of prior treatment experience but may have greater efficacy and an improved benefit/risk profile in those with fewer prior treatments.
Study context
- Population
- Patients with RA with distinct treatment histories in phase II/III tofacitinib trials
- Participants
- 537 / 3,113 / 782
- Comparison
- Tofacitinib 5 or 10 mg twice daily vs placebo, as monotherapy or with csDMARDs, by prior inadequate response
- Non-MTX csDMARD-IRn = 537
- MTX-IRn = 3,113
- bDMARD-IRn = 782
- Outcome
- ACR20/50/70 response and DAS28-4(ESR) remission (<2.6); changes from baseline in DAS28-4(ESR) and HAQ-DI
- Follow-up
- Month 3
Methodological detailsplacebo-controlled, subgroup analysis by previous treatment
- Placebo-controlled
- Subgroup analysis by previous treatment
Pooled result
As reported in the abstract
Efficacy by previous treatment
- Efficacy generally improved with tofacitinib (both doses) vs placebo in each population
- Efficacy with tofacitinib numerically more favorable in non-MTX csDMARD-IR vs MTX-IR or bDMARD-IR
- Post hoc
Original publication
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials. Arthritis Res Ther. Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →